Key result
Non-invasive transcutaneous vagus nerve stimulation may improve exercise tolerance, but generalizability is limited by a narrow age range (30-39 years) and inclusion of overweight participants.
Answers are grounded in this paper and cite their sources.
This commentary emphasizes the need for broader age and weight inclusion in future tVNS trials to ensure generalizability of its cardiovascular and exercise capacity benefits.
This commentary refers to ‘Non-invasive vagus nerve stimulation and exercise capacity in healthy volunteers: a randomized trial’, by Ackland et al., https://doi.org/10.1093/eurheartj/ehaf037. We have read the recent article by Ackland et al.1 published in the European Heart Journal titled ‘Non-invasive vagus nerve stimulation and exercise capacity in healthy volunteers: a randomized trial.’ This study provides strong evidence that non-invasive transcutaneous vagus nerve stimulation (tVNS) can serve as a low-risk, convenient, non-pharmacological intervention for autonomic nerve regulation. Through dual validation via physiological indicators and transcriptomics analysis, the research suggests that tVNS could potentially offer personalized solutions for improving exercise tolerance and promoting cardiovascular health. However, I have noticed some details that may affect the generalizability and reliability of the conclusions. As people age, there are physiological changes in hormone levels and skeletal muscle mass, along with a decline in cardiopulmonary function and anti-inflammatory capacity.2 Additionally, older populations often have multiple chronic diseases, such as COPD, coronary artery disease, and diabetes, which may influence the effectiveness of tVNS. Although the inclusion criteria did not specify an age limit, the actual participants’ age range was quite narrow, between 30 and 39 years. This means that the conclusion about tVNS’s improvement in cardiopulmonary function is difficult to generalize to other age groups, especially the elderly. While the title of the paper clearly mentions ‘healthy volunteers’, the text includes some overweight participants. Overweight and obesity have been shown in multiple studies to negatively affect cardiopulmonary function, induce systemic inflammation, and increase the risk of various chronic diseases.3–5 Whether due to the age issue or the incorrect phrasing of ‘healthy volunteers,’ these factors affect the generalizability of the study's conclusions. I suggest that future research should include a broader population across different age groups and body weights, and conduct subgroup analysis to determine the applicability and differences of tVNS in various groups.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) conducted a letter in Healthy volunteers. Non-invasive transcutaneous vagus nerve stimulation (tVNS) was evaluated on Exercise tolerance and cardiovascular health. Non-invasive transcutaneous vagus nerve stimulation may improve exercise tolerance, but generalizability is limited by a narrow age range (30-39 years) and inclusion of overweight participants.
Synapse has enriched 10 related papers. Consider them for comparative context: